Takeda Pharmaceutical Co Ltd ADR

Yahoo Finance • 18 hours ago

Axsome Therapeutics Acquires Selective PDE10A Inhibitor Balipodect for the Treatment of Schizophrenia and Other Neuropsychiatric Conditions

Axsome Therapeutics, Inc. Axsome obtains exclusive global rights to balipodect, a potentially first-in-class selective phosphodiesterase 10A inhibitor Acquisition further expands Axsome’s industry-leading CNS portfolio with a novel mecha... Full story

Yahoo Finance • 20 hours ago

Renal Cell Carcinoma Market Report 2026-2030 & 2035: Increasing Immunotherapy and Precision Oncology Programs Drives Market Expansion, Reaching USD 6.09 Billion by 2030

Dublin, April 01, 2026 (GLOBE NEWSWIRE) -- The "Renal Cell Carcinoma Market Report 2026" has been added to ResearchAndMarkets.com's offering. The report provides a comprehensive analysis, depicting global market size, regional shares,... Full story

Yahoo Finance • 3 days ago

Alumis' Drug 'Very Positive' for Treatment of Psoriasis, Systemic Lupus Erythematosus, Oppenheimer Says

Alumis' (ALMS) recent phase 3 results for its psoriasis treatment envudeucitinib is "very positive" PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium... Full story

Yahoo Finance • 3 days ago

Recurrent Head and Neck Cancer Squamous Cell Carcinoma Markets and Competition Outlook 2026-2030: Personalized Medicine Drives Revenue Growth, Reaching $4.61 Billion by 2030

Dublin, March 30, 2026 (GLOBE NEWSWIRE) -- The "Recurrent Head and Neck Cancer Squamous Cell Carcinoma Market Report 2026" has been added to ResearchAndMarkets.com's offering. The report offers comprehensive insights on market size, reg... Full story

Yahoo Finance • 4 days ago

Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care

About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safet... Full story

Yahoo Finance • 8 days ago

Weave Bio Establishes Inaugural Strategic Advisory Board to Shape the Future of AI-Driven Regulatory Science

Board unites senior regulatory, quality, investment, and AI leaders from Boehringer Ingelheim, Takeda, Gilead Sciences, Serrado Capital, and Stanford University SAN FRANCISCO, March 25, 2026--(BUSINESS WIRE)--Weave Bio, the leader in AI-n... Full story

Yahoo Finance • 25 days ago

FDA Grants Priority Review for Takeda (TAK) and Protagonist’s Rusfertide in PV Treatment

Takeda Pharmaceutical Company Limited (NYSE:TAK) is one of the most promising stocks under $20. On March 2, Takeda and Protagonist Therapeutics announced that the US FDA accepted the New Drug Application and granted Priority Review for rus... Full story

Yahoo Finance • 26 days ago

Eli Lilly Weighs Employer Growth Potential Against Fresh Actos Legal Risk

Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Eli Lilly (NYSE:LLY) launched its Employer Connect platform to expand access to its obesity medicine Zepbound through U.S.... Full story

Yahoo Finance • last month

CORRECTION: Protagonist Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

(This release updates the release that posted earlier on February 25, 2026 to update the sub headlines.) NDA for rusfertide submitted to the US Food and Drug Administration (FDA), with potential approval and launch this year Company expe... Full story

Yahoo Finance • last month

Protagonist Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

NDA for rusfertide submitted to the US Food and Drug Administration (FDA), with potential approval and launch this year Company expects to opt-out of the 50:50 profit and loss sharing arrangement for rusfertide with Takeda during a 90-day... Full story

Yahoo Finance • last month

Personalized Medicine Market Competitive Landscape Report 2025: Company Analysis, Company Profiles, Strategic Developments, Mergers, Product Innovations, Revenue Insights, and Future Forecasts to 2033

Company Logo Personalized Medicine Market Poised for Tremendous Growth by 2033The global personalized medicine market, valued at approximately US$ 585.53 billion in 2026, is projected to soar to nearly US$ 1.00 trillion by 2033. A report... Full story

Yahoo Finance • last month

FDA Grants Breakthrough Status To Johnson & Johnson's Cancer Drug For Advanced Head and Neck Cancer

The U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation for subcutaneous Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) as a monotherapy for adults with advanced head and neck squamous cell carcinoma. F... Full story

Yahoo Finance • last month

Novo Nordisk nominates three new board directors, two with pharma experience

[New Nordisk] hapabapa * Novo Nordisk has nominated Jan van de Winkel and Ramona Sequeira, both of whom have pharmaceutical industry experience, for its board. * Van de Winkel co-founded Genmab (GMAB [https://seekingalpha.com/symbol/... Full story

Yahoo Finance • last month

Positive Phase 3 Data Demonstrate Potential for ENTYVIO® (vedolizumab) to Address Treatment Gap for Children and Adolescents with Moderate to Severe Ulcerative Colitis

Pivotal Phase 3 global KEPLER study of vedolizumab intravenous (IV) in pediatric patients ages 2 to 17, who had an inadequate response to either conventional treatment options or tumor necrosis factor (TNF) antagonists, found nearly half (... Full story

Yahoo Finance • last month

HALOZYME REPORTS FULL YEAR 2025 RECORD REVENUE OF $1.4 BILLION AND REITERATES STRONG 2026 FINANCIAL GUIDANCE

Full Year 2025 Total Revenue Increased 38% YOY to Record $1.397 billion Full Year 2025 Royalty Revenue Increased 52% YOY to Record $868 million Completed Acquisitions of Elektrofi's Hypercon™ Technology and Surf Bio's Hyperconcentration T... Full story

Yahoo Finance • last month

Assessing Takeda Pharmaceutical (TSE:4502) Valuation After A Strong Run In Recent Months

Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. What recent returns suggest about Takeda Pharmaceutical shares Takeda Pharmaceutical (TSE:4502) has drawn attention a... Full story

Yahoo Finance • 2 months ago

H.C. Wainwright Raises Protagonist Therapeutics, Inc. (PTGX) Target to $117, Reiterates Buy

We recently published an article titled 10 Best Long Term Healthcare Stocks to Buy. On January 30, H.C. Wainwright raised its price target on Protagonist Therapeutics, Inc. (NASDAQ:PTGX) to $117 from $80 and reiterated a Buy rating. The f... Full story

Yahoo Finance • 2 months ago

U.S. Food and Drug Administration Accepts New Drug Application and Grants Priority Review for Takeda’s Oveporexton (TAK-861) as a Potential First-in-Class Therapy for Narcolepsy Type 1

This FDA Acceptance is a Milestone for People Living with Narcolepsy Type 1 Who Need New and Different Treatment Options Oveporexton is an Orexin Agonist Designed to Restore Orexin Signaling and Address the Underlying Orexin Deficiency tha... Full story

Yahoo Finance • 2 months ago

Is Takeda’s Upgraded FY2025 Outlook And New PID Therapy Altering The Investment Case For Takeda (TSE:4502)?

In late January 2026, Takeda Pharmaceutical reported nine-month FY2025 results showing sales of ¥3,411.18 billions and net income of ¥216.08 billions, alongside slightly higher earnings per share year-on-year, and raised its full-year 2025... Full story

Yahoo Finance • 3 months ago

Blending Data and Local Knowledge To Enable Sustainable Outcomes

This interview is part of Takeda's Access to Medicine Report. Read the full interview here. NORTHAMPTON, MA / ACCESS Newswire / December 29, 2025 / In February 2024, Takeda entered into a partnership with CARE, a global leader in the figh... Full story